KALV

KALVISTA PHARMACEUTICALS, INC.

KALV · CIK 1348911 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$50M
20182025
Net Income−$183M
20182025
Operating CF−$153M
20182025
Free Cash Flow−$153M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.1B——$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.2B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B
Net Income$-0.2B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-3.69$-3.44$-3.33$-3.36————
EPS (Diluted)$-3.69$-3.44$-3.33$-3.36————

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.3B$0.2B$0.2B$0.2B$0.3B$0.1B$0.1B$0.1B
Current Assets$0.2B$0.2B$0.2B$0.2B$0.3B$0.1B$0.1B$0.1B
Cash & Equivalents$0.1B$0.0B$0.1B$0.0B$0.1B$0.0B$0.0B$0.1B
Total Liabilities————————
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.1B$0.2B$0.2B$0.2B$0.3B$0.1B$0.1B$0.0B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.2B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B$0.0B
Investing Cash Flow$0.1B$-0.1B$0.0B$0.1B$-0.1B$0.0B$-0.1B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.2B$0.2B$0.1B$0.0B$0.2B$0.0B$0.1B$0.0B
← Companies